Meet Novartis-Penn Center for Advanced Cellular Therapies - 2017 FOYA Honorable Mention Winner
Novartis Institutes for BioMedical Research & University of Pennsylvania Health System is one of three 2017 Facility of the Year® Honorable Mention winners for their Center for Advanced Cellular Therapies project in Philadelphia, Pennsylvania USA. Projects selected for recognition of an Honorable Mention Award are projects that utilize new technology or are located in a challenging region of the world. These projects do not win for a specific category, but are clearly successful projects that overcame significant challenges in planning, execution, and delivery and deserve recognition for their achievements.
The Center for Advanced Cellular Therapies (CACT) brings together Penn Medicine’s intellectual resources combined with a pharmaceutical industry leader in Novartis, with the mutual goal to find more effective treatments for cancer. Located on Penn Medicine’s campus in Philadelphia, amidst both clinical care and laboratory facilities, the 30,000 sf CACT is poised to become the core center for research and early clinical development of personalized cellular therapies for cancer. This facility will expand on Penn’s groundbreaking research using Chimeric Antigen Receptor (CAR) technology, which enables a patient’s own immune cells to be reprogrammed outside of their body and re-infused to “hunt” for and potentially destroy tumors. The innovative design concepts implemented in the center have:
Increased program efficiency by 25%
Doubled process efficiency
Maximized daylighting
Increased communication and collaboration between researchers
The CACT is poised to become a true facility of the future – an epicenter for the research and early clinical development of personalized cellular therapies for many forms of cancer. The facility is a shining example of a successful academic/corporate partnership where the whole is greater than the sum of its parts. Together, the institutions can better expedite novel therapies for diseases of all kinds.
ISPE congratulates the Novartis Institutes for BioMedical Research & the University of Pennsylvania Health System team for their achievements and their Facility of the Year award-winning entry. Learn more about the 2017 FOYA Honorable Mention winner.
To meet the biopharmaceutical industry’s duty to manufacture safe and effective therapies for patients, a robust quality system is fundamental to success. A quality system should link to quality culture and prioritize focusing on quality, led by management, that fosters sustainable compliance and consistent production of high-quality drugs. Strong quality culture attributes include a proactive...
Stability sampling and testing are key to ensuring that products maintain safety, identity, strength, purity, and quality throughout their claimed shelf life. It is also a regulatory requirement per ICH Q5. However, storing product samples in different environmental conditions, testing those samples for three to five years (or more) after initial manufacture, and properly analyzing and...
ISPE hosted more than 450 attendees in person and virtually for the 2024 ISPE Aseptic Conference in Vienna, Austria. Keynotes and education sessions provided a comprehensive overview of key topics and trends...